Organogenesis Holdings (ORGO) EBT Margin (2017 - 2026)
Organogenesis Holdings' (ORGO) quarterly EBT Margin came in at 183.93% in Q1 2026, down 15419.0% year-on-year from N/an in Q1 2025, and down 754.23% quarter-over-quarter from 28.11% in Q4 2025.
Organogenesis Holdings (ORGO) EBT Margin (2017 - 2026) Analysis & Trends
Organogenesis Holdings' EBT Margin history runs 10 years deep, the most recent figure standing at 183.93% for Q1 2026.
- On a quarterly basis, EBT Margin fell 15419.0% year-over-year to 183.93% in Q1 2026; TTM through Mar 2026 was 0.83%, a 612.0% increase from a year earlier, with the FY2025 full-year figure at 8.33%, up 891.0% from the prior year.
- EBT Margin slipped to 183.93% in Q1 2026 per ORGO's latest filing, from 28.11% in the prior quarter.
- Across five years, EBT Margin topped out at 28.11% in Q4 2025 and bottomed at 183.93% in Q1 2026.
- The 5-year median for EBT Margin is 1.04% (2022), against an average of 9.38%.
- Across the five-year window, EBT Margin jumped 2002 bps in 2025 and slumped 15419 bps in 2026, its largest moves.
- Year by year, EBT Margin stood at 7.58% in 2022, then plunged by 124 bps to 1.8% in 2023, then surged by 549 bps to 8.1% in 2024, then soared by 247 bps to 28.11% in 2025, then tumbled by 754 bps to 183.93% in 2026.
- Per Business Quant, the three latest ORGO EBT Margin figures stand at 183.93% (Q1 2026), 28.11% (Q4 2025), and 14.03% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 10.97% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 33.51% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -41.57% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 40.73% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -7.05% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 30.30% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.35% |
| 10 | Organogenesis Holdings | 310.55 Mn | 218.45 Mn | 11.46 Mn | -183.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -183.93% |
| Dec 31, 2025 | 28.11% |
| Sep 30, 2025 | 14.03% |
| Jun 30, 2025 | -11.72% |
| Mar 31, 2025 | -29.74% |
| Dec 31, 2024 | 8.10% |
| Sep 30, 2024 | 5.06% |
| Jun 30, 2024 | -11.16% |
| Mar 31, 2024 | -3.95% |
| Dec 31, 2023 | -1.80% |
| Sep 30, 2023 | 7.04% |
| Jun 30, 2023 | 7.82% |
| Mar 31, 2023 | -4.30% |
| Dec 31, 2022 | 7.58% |
| Sep 30, 2022 | 1.04% |
| Jun 30, 2022 | 9.21% |
| Mar 31, 2022 | -0.89% |
| Dec 31, 2021 | 14.77% |
| Sep 30, 2021 | 11.32% |
| Jun 30, 2021 | 17.19% |